MRCP
HZNP

Maple Rock Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Maple Rock Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-385,000
Closed -$6.98M – 26
2016
Q3 		$6.98M Buy
+385,000
New +$7.52M 2.64% 16

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Maple Rock Capital Partners's HZNP Position: Q4 2016 in Review

Maple Rock Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 385,000 shares — an estimated $6.98M sold.

Maple Rock Capital Partners first reported a position in HZNP in Q3 2016 and held it in 1 quarter. The position peaked at $6.98M in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

  • Maple Rock Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
  • Maple Rock Capital Partners sold 385,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $6.98M.
  • Maple Rock Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 1 quarter.
  • Maple Rock Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $6.98M in Q3 2016.
  • 234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Maple Rock Capital Partners's 13F filing for Q4 2016, filed 14 Feb 2017.